文献速递关节外科

ε-氨基己酸减少全髋与全膝关节置换术后失血与输血

Epsilon Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Hip and Total Knee Arthroplasty.
PubMed 文献 · J Arthroplasty · 2017-08-24

该回顾性研究比较了实施ε-氨基己酸(EACA)方案前后各一年行初次全髋或全膝关节置换术患者的失血与输血情况,EACA组血红蛋白下降及输血发生率均显著低于对照组,静脉血栓栓塞并发症无差异,作者认为EACA是氨甲环酸的低成本替代选择。

要点

  • EACA组血红蛋白下降2.7±0.8 mg/dL,显著低于对照组3.4±1.1 mg/dL(P < .0001)。
  • EACA组输血发生率2.7%,显著低于对照组25.4%(P < .0001)。
  • 两组静脉血栓栓塞并发症无差异。

核心结论

  • 实施EACA方案后初次关节置换患者血红蛋白下降和输血均减少,EACA是氨甲环酸的低成本替代选择。

研究设计与样本

  • 回顾性比较实施EACA方案前一年与后一年行初次全髋或全膝关节置换术的患者,排除翻修手术。

主要发现

  • EACA组185例,对照组184例,期间手术技术和主刀医生无变化。
  • EACA组血红蛋白下降2.7±0.8 mg/dL,显著低于对照组3.4±1.1 mg/dL(P < .0001)。
  • EACA组输血发生率2.7%,显著低于对照组25.4%(P < .0001)。
  • 两组静脉血栓栓塞并发症无差异。

临床怎么用

  • 作者认为EACA可作为氨甲环酸的低成本替代选择,用于初次关节置换患者减少失血与输血。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Total hip and knee arthroplasty (THA and TKA) are associated with significant blood loss and some patients require postoperative blood transfusion. While tranexamic acid has been studied extensively among this population, we tested the hypothesis that epsilon aminocaproic acid (EACA) can reduce blood loss and transfusion after joint arthroplasty. METHODS: In April 2014, our Veterans Affairs Medical Center introduced a protocol to administer EACA during THA and TKA. No antifibrinolytics were used previously. We retrospectively compared blood loss and incidence of transfusion among patients who underwent primary arthroplasty in the year before standardized administration of EACA with patients having the same procedures the following year. Blood loss was measured as delta hemoglobin (preoperative hemoglobin - hemoglobin on postoperative day 1). All patients undergoing primary THA or TKA were included. Patients having revision surgery were excluded. RESULTS: We identified 185 primary arthroplasty patients from the year before and 184 from the year after introducing the EACA protocol. There were no changes in surgical technique or attending surgeons during this period. Delta hemoglobin was significantly lower in the EACA group (2.7 ± 0.8 mg/dL) compared to the control group (3.4 ± 1.1 mg/dL) (P < .0001). The incidence of blood transfusion was also significantly lower in the EACA group (2.7%) compared to the control group (25.4%) (P < .0001). There was no difference in venous thromboembolic complications between groups. CONCLUSION: We demonstrated reductions in hemoglobin loss and transfusion following introduction of the EACA protocol in patients undergoing primary arthroplasty. EACA offers a lower cost alternative to TXA for reducing blood loss and transfusion in this population.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Hobbs JC, Welsby IJ, Green CL, et al. Epsilon Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Hip and Total Knee Arthroplasty. J Arthroplasty. 2017. PMID: 28939033. doi:10.1016/j.arth.2017.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。